Novogene Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 2,225

Employees

  • Stock Symbol
  • 688315

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.41
  • (As of Thursday Closing)

Novogene General Information

Description

Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.

Contact Information

Website
novogene.com
Formerly Known As
Beijing Novogene Bioinformatics Technology
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Building 301, Zone A10 Jiuxianqiao North Road
  • Chaoyang District
  • Beijing, 100015
  • China
+86 010
Primary Industry
Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Building 301, Zone A10 Jiuxianqiao North Road
  • Chaoyang District
  • Beijing, 100015
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novogene Stock Performance

As of 19-Nov-2026, Novogene’s stock price is $2.41. Its current market cap is $1B with 416M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.41 $2.54 $1.69 - $3.50 $1B 416M 19.1M $0.05

Novogene Financials Summary

As of 30-Sep-2026, Novogene has a trailing 12-month revenue of $334M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 989,105 584,810 550,010 1,244,070
Revenue 333,589 307,264 294,242 282,988
EBITDA 24,507 46,946 52,826 50,421
Net Income 21,786 23,215 27,425 25,168
Total Assets 585,589 563,479 498,209 507,071
Total Debt 9,700 10,211 5,860 5,950
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novogene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novogene‘s full profile, request access.

Request a free trial

Novogene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life sc
Biotechnology
Beijing, China
2,225 As of 2025

Shenzhen, China
 

Atlanta, GA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novogene Competitors (25)

One of Novogene’s 25 competitors is BGI Genomics, a Formerly VC-backed company based in Shenzhen, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BGI Genomics Formerly VC-backed Shenzhen, China
Otogenetics Corporation Atlanta, GA
Macrogen Oceania Corporation Bella Vista, Australia
Nucleome Informatics Pvt Corporation Hyderabad, India
WuXi AppTec Formerly PE-Backed Shanghai, China
You’re viewing 5 of 25 competitors. Get the full list »

Novogene Patents

Novogene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024066514-A1 High-throughput preparation method and device for omics product Inactive 30-Sep-2022
DE-112023002136-T5 Method and apparatus for high-throughput production of omics products Pending 30-Sep-2022

Novogene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novogene Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novogene‘s full profile, request access.

Request a free trial

Novogene Investments (4)

Novogene’s most recent deal was a Corporate Asset Purchase with PacBio (Portfolio of Revio Sequencers). The deal was made on 10-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PacBio (Portfolio of Revio Sequencers) 10-Jan-2024 Corporate Asset Purchase Buildings and Property
Zheyuan Technology 15-Jun-2022 Later Stage VC Decision/Risk Analysis
AiJiaZaoCha 28-Sep-2016 Early Stage VC Laboratory Services (Healthcare)
NovogeneAIT Genomics Singapore 07-Sep-2016 Joint Venture Laboratory Services (Healthcare)
To view Novogene’s complete investments history, request access »

Novogene ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Services

Subindustry

Rank

Percentile

To view Novogene’s complete esg history, request access »

Novogene FAQs

  • When was Novogene founded?

    Novogene was founded in 2011.

  • Where is Novogene headquartered?

    Novogene is headquartered in Beijing, China.

  • What is the size of Novogene?

    Novogene has 2,225 total employees.

  • What industry is Novogene in?

    Novogene’s primary industry is Biotechnology.

  • Is Novogene a private or public company?

    Novogene is a Public company.

  • What is Novogene’s stock symbol?

    The ticker symbol for Novogene is 688315.

  • What is the current stock price of Novogene?

    As of 19-Nov-2026 the stock price of Novogene is $2.41.

  • What is the current market cap of Novogene?

    The current market capitalization of Novogene is $1B.

  • What is Novogene’s current revenue?

    The trailing twelve month revenue for Novogene is $334M.

  • Who are Novogene’s competitors?

    BGI Genomics, Otogenetics, Macrogen Oceania, Nucleome Informatics Pvt, and WuXi AppTec are some of the 25 competitors of Novogene.

  • What is Novogene’s annual earnings per share (EPS)?

    Novogene’s EPS for 12 months was $0.05.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process